On the contrary, fenofibrate ameliorates diabetic nephropathy by way of the activation of AMPK-PGC-1α-ERR-1α signaling and the subsequent inactivation of PI3K-Akt and dephosphorylation of FoxO3a and downregulation of SREBP-1 and ChREBP-1, which reverses renal lipid accumulation, apoptotic renal injury and oxidative stress. This evidence concerns the gene PPARGC1A and diabetic kidney disease.